Orthofix Names New CEO

Orthofix Medical Inc., a global medical device company focused on musculoskeletal products and therapies, has named Jon Serbousek as president of its Global Spine business effective August 5, and the successor to Brad Mason, the company’s retiring president and CEO, to be effective November 1.
 
A seasoned executive with more than 30 years’ experience in the medical device and biotech industries, Serbousek served in several leadership positions at Biomet Inc., including Worldwide President of Biomet Biologics, Worldwide Group President of Orthopedics, and President of U.S. Orthopedics. Prior to joining Biomet, he held various general management positions within Medtronic Inc. including Worldwide Division President, Spine, Worldwide Vice President and General Manager of Biologics for their Spine and Biologics business. Additionally, Serbousek spent 13 years with DePuy Orthopedics, a Johnson & Johnson company where he served in numerous roles of increasing responsibility, including the Vice President of Marketing and Product Development and as Vice President of Spinal Operations.
 
“Jon’s expertise and proven track record are perfectly aligned with our business composition and make him an exceptional choice to lead the company as president and CEO,” said Brad Mason, Orthofix president and CEO. “With the recent leadership change in our spine business, I am pleased that Jon has agreed to serve as the president of Global Spine on an interim basis. This will give him time to focus on our needs and opportunities in that business before he takes on the broader CEO role, which should help ensure a seamless leadership transition for the benefit of all Orthofix stakeholders.”
 
“Today’s announcement underscores our commitment to finding a leader who can build on the Company’s current momentum and opportunities in the years ahead,” said Orthofix Chairman of the Board, Ron Matricaria. “After an extensive search, we have found that leader in Jon. His many years of experience and solid understanding of the medical device markets that Orthofix competes in, make him well qualified to lead the company.”
 
“I am excited to join Orthofix,” said Jon Serbousek. “It is an honor to assume this leadership role, particularly at a time when the company is so well positioned for future shareholder value creation. I look forward to working with the great team at Orthofix as we continue to shape the company for the years ahead.”
 
Serbousek has held numerous board positions at for profit and not-for-profit organizations. He earned his BS in Engineering from Washington State University, his MS in Bioengineering from the University of Utah and later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland.
 
As an inducement to enter into employment with Orthofix, Serbousek was granted restricted stock units representing approximately 14,743 shares of Orthofix common stock and stock options to purchase approximately 50,711 shares of Orthofix common stock. The exercise price of the stock options will be the August 5, 2019 closing price of the common stock on the NASDAQ Stock Market. Subject to certain further requirements set forth in the award agreements, the restricted stock unit and option awards vests in 25 percent annual increments beginning on the first anniversary of grant. The grants, which were approved by Orthofix’s Board of Directors and Compensation Committee, were made under standalone inducement award agreements approved pursuant to NASDAQ Marketplace Rule 5635(c)(4).